urea and omecamtiv mecarbil

urea has been researched along with omecamtiv mecarbil in 125 studies

Research

Studies (125)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (1.60)	29.6817
2010's	61 (48.80)	24.3611
2020's	62 (49.60)	2.80

Authors

Authors	Studies
Teerlink, JR	1
Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V	1
Abarzúa, P; Depre, C; Dhar, SK; Malik, FI; Morgans, DJ; Shen, YT; Vatner, SF; Zhao, X	1
Campia, U; Gheorghiade, M; Nodari, S	1
Fox, CJ; Kaye, AD; Liu, H; Zhang, S	1
Leinwand, LA; Moss, RL	1
Anderson, RL; Baliga, R; Brejc, K; Cox, DR; Elias, KA; Finer, JT; Garard, M; Godinez, G; Hartman, JJ; Kass, DA; Katori, T; Kawas, R; Kraynack, E; Lee, KH; Lenzi, D; Lu, PP; Malik, FI; Morgan, BP; Morgans, DJ; Muci, A; Niu, C; Pierce, DW; Pokrovskii, M; Qian, X; Rodriguez, H; Sakowicz, R; Shen, YT; Suehiro, I; Sueoka, SH; Sylvester, S; Tochimoto, T; Valdez, C; Vatner, SF; Wang, W	1
Bers, DM; Harris, SP	1
Malik, FI; Morgan, BP	1
Dickstein, K	1
Bee, R; Chen, MM; Clarke, CP; Elliott, L; Escandon, RD; Goldman, JH; Habibzadeh, MR; Lee, JH; Malik, FI; Saikali, KG; Schiller, NB; Teerlink, JR; Wolff, AA	1
Clarke, CP; Cleland, JG; Francis, DP; Goldman, JH; Greenberg, BH; Lang, CC; Lee, JH; Malik, FI; Mayet, J; Mc Murray, JJ; Monaghan, M; Neyses, L; Nifontov, EM; Saikali, KG; Saltzberg, M; Senior, R; Shaburishvili, T; Teerlink, JR; Tsyrlin, VA; Wasserman, SM; Wolff, AA	1
Asselbergs, FW; Doevendans, PA; Meijs, MF	1
Ezekowitz, JA	1
Fang, W; Ma, Y; Mou, T; Peng, C; Zhang, M; Zhang, X; Zhao, Z	1
Albert, NM; Butler, J; Carson, PE; Collins, SP; Colvin-Adams, M; Dimarco, JP; Ezekowitz, JA; Fang, JC; Givertz, MM; Hernandez, AF; Hershberger, RE; Katz, SD; Krishnamani, R; Rogers, JG; Spertus, JA; Starling, RC; Stevenson, WG; Stough, WG; Sweitzer, NK; Tang, WH; Teerlink, JR; Walsh, MN; Westlake Canary, CA	1
Pollesello, P	1
Valentova, M; von Haehling, S	1
Balligand, JL; Bauersachs, J; Clerk, A; De Windt, L; Heymans, S; Hilfiker-Kleiner, D; Hirsch, E; Iaccarino, G; Knöll, R; Leite-Moreira, AF; Lourenço, AP; Mayr, M; Tarone, G; Thum, T; Tocchetti, CG	1
Ajtai, K; Burghardt, TP; Wang, Y	1
Chen, MM; Chou, W; Eisenberg, P; Escandón, R; Greenberg, BH; Lee, JH; Malik, FI; Megreladze, I; Saikali, KG; Shaburishvili, T; Treshkur, T; Wasserman, SM; Wolff, AA	1
Belknap, B; Forgacs, E; Liu, Y; White, HD; Winkelmann, DA	1
Houdusse, AM; Pylypenko, O; Shima, A; Song, L; Sweeney, HL; Yang, Z	1
Aksel, T; Choe Yu, E; Ruppel, KM; Spudich, JA; Sutton, S	1
Chow, AT; Ma, P; Malik, FI; Vu, T; Wang, YM; Xiao, JJ	1
Aasum, E; Bakkehaug, JP; Boardman, N; Engstad, ET; How, OJ; Kildal, AB; Larsen, TS; Myrmel, T; Næsheim, T; Rønning, L	1
Li, BH; Ryba, DM; Solaro, RJ; Utter, MS; Wolska, BM	1
dos Remedios, CG; Gresham, KS; Li, A; Mamidi, R; Stelzer, JE	1
Forgacs, E; Miller, MT; Stock, AM; Winkelmann, DA	1
Dorhout, B; Liu, LC; Teerlink, JR; van der Meer, P; Voors, AA	1
Bezemer, JM; Correll, TL; Kennedy, MT; Roberts, SW; Subramanian, R; Walker, SD	1
Alvarez, P; Banfield, C; Johnson, J; Malik, F; Monsalvo, ML; Palaparthy, R; Smith, B; Yan, L	1
Cleland, JGF; Dickstein, K; Ezekowitz, JA; Felker, GM; Filippatos, GS; Kim, JB; Knusel, B; Lei, L; Malik, FI; McMurray, JJV; Metra, M; Ponikowski, P; Teerlink, JR; Wasserman, SM; Wolff, AA	1
Broughton, KM; Henze, MP; Li, J; Lin, YH; Russell, B; Sanchez-Freire, V; Sarmah, E; Solaro, RJ; Warren, CM	1
Butler, J; Hamo, CE; Moin, DS; Sackheim, J	1
Anatchkova, M; Chau, D; Malik, FI; Oko-Osi, H; Patrick, DL; Spertus, J; Teerlink, JR; von Maltzahn, R; Wiklund, I	1
Banyasz, T; Horvath, B; Kistamas, K; Magyar, J; Masuda, L; Nanasi, PP; Papp, Z; Szentandrassy, N; Vaczi, K	1
Adams, KF; Cleland, JG; Ezekowitz, JA; Felker, GM; Goudev, A; Honarpour, N; Johnston, J; Macdonald, P; Malik, FI; McMurray, JJ; Metra, M; Mitrovic, V; Monsalvo, ML; Ponikowski, P; Serpytis, P; Solomon, SD; Spinar, J; Teerlink, JR; Tomcsányi, J; Vandekerckhove, HJ; Voors, AA	1
Lim, GB	1
Blair, CA; Campbell, KS; Fetrow, CM; Previs, MJ; Swenson, AM; Tang, W; Unrath, WC; Yengo, CM	1
Muretta, JM; Rohde, JA; Thomas, DD	1
Psotka, MA; Teerlink, JR	1
Almássy, J; Gaburjakova, J; Gaburjakova, M; Nánási, P	1
Hartman, JJ; Houdusse, A; Malik, FI; Planelles-Herrero, VJ; Robert-Paganin, J	1
Chandra, M; Gollapudi, SK; Reda, SM	1
Chien, FJ; Eisen, HJ; Kim, DH	1
Almássy, J; Bányász, T; Horváth, B; Magyar, J; Nánási, PP; Papp, Z; Szentandrássy, N; Tóth, A; Veress, R	1
Irving, M; Kampourakis, T; Sun, YB; Zhang, X	1
Fornili, A; Hashem, S; Tiberti, M	1
Almassy, J; Gaburjakova, M; Komaromi, I; Nanasi, P	1
Annoni, F; El-Oumeiri, B; Herpain, A; Jespers, P; Mc Entee, K; van de Borne, P; Van Nooten, G; Vanden Eynden, F	1
Almássy, J; Komáromi, I; Nánási, P	1
Kawana, M; Liu, C; Ruppel, KM; Song, D; Spudich, JA	1
Barua, B; Goldman, YE; Greenberg, MJ; Ostap, EM; Winkelmann, DA; Woody, MS	1
Anker, SD; Balligand, JL; Bauersachs, J; Brutsaert, D; Carrier, L; Chlopicki, S; Cleland, JG; de Boer, RA; de Keulenaer, G; Dietl, A; Eschenhagen, T; Fischmeister, R; Hamdani, N; Harjola, VP; Heinzel, FR; Heymans, S; Hilfiker-Kleiner, D; Holzmeister, J; Limongelli, G; Linke, WA; Lund, LH; Lyon, AR; Maack, C; Manstein, DJ; Masip, J; Mebazaa, A; Metra, M; Metzger, J; Mueller, C; Papp, Z; Pieske, B; Ponikowski, P; Ristić, A; Ruschitzka, F; Seferović, PM; Skouri, H; Tocchetti, CG; Yilmaz, MB; Zimmermann, WH	1
Bakkehaug, JP; How, OJ; Kildal, AB; Myrmel, T; Rødland, L; Rønning, L	1
Agarwal, R; Chen, CS; Chopra, A; Cicconet, M; Ewoldt, J; Garfinkel, AC; Mücke, M; Neyazi, M; Pourquié, O; Rao, J; Schmid, M; Seidman, CE; Seidman, JG; Sharma, A; Toepfer, CN; Willcox, JAL	1
Seidman, CE; Seidman, JG; Yotti, R	1
Awinda, PO; Kieu, TT; Tanner, BCW	1
Bauersachs, J; Berliner, D	1
Desetty, R; Tang, W; Unrath, WC; Yengo, CM	1
How, OJ; Kildal, AB; Myrmel, T; Rødland, L; Rønning, L	1
Aghdam, RM; Emami, SH; Kiaie, N; Rabbani, S; Tafti, HA	1
Granzier, H; Karimi, E; Kolb, J; Lee, EJ; Lindqvist, J	1
Lüscher, TF	1
Braren, I; Denning, C; Eschenhagen, T; Hansen, A; Mannhardt, I; Saleem, U	1
Büchele, G; Diaz, R; Felker, GM; Honarpour, N; Kurtz, CE; Legg, JC; Malik, FI; McMurray, JJV; Metra, M; Solomon, SD; Teerlink, JR; Varin, C	1
Berg, VY; Bershitsky, SY; Kochurova, AM; Kopylova, GV; Nabiev, SR; Nikitina, LV; Shchepkin, DV	1
Mehmood, M	1
Caremani, M; Gallart, C; Governali, S; Linari, M; Lombardi, V; Ottenheijm, C; Pertici, I; Piazzesi, G; Stienen, G	1
Ballan, N; Gepstein, L; Keller, GM; Shaheen, N	1
Gao, B; Qu, Y; Sutherland, W; Vargas, HM	1
Abbasi, SA; Adams, KF; Anand, I; Arias-Mendoza, A; Biering-Sørensen, T; Böhm, M; Bonderman, D; Cleland, JGF; Corbalan, R; Crespo-Leiro, MG; Dahlström, U; Diaz, R; Echeverria Correa, LE; Fang, JC; Felker, GM; Filippatos, G; Fonseca, C; Goncalvesova, E; Goudev, AR; Howlett, JG; Kurtz, CE; Lanfear, DE; Legg, JC; Lund, M; Macdonald, P; Malik, FI; Mareev, V; McMurray, JJV; Metra, M; Momomura, SI; O'Meara, E; Parkhomenko, A; Ponikowski, P; Ramires, FJA; Serpytis, P; Sharpsten, L; Sliwa, K; Solomon, SD; Spinar, J; Suter, TM; Teerlink, JR; Tomcsanyi, J; Vandekerckhove, H; Varin, C; Vinereanu, D; Voors, AA; Yilmaz, MB; Zannad, F	1
Bernier, TD; Buckley, LF	1
Abbasi, SA; Cleland, JGF; Felker, GM; Globe, G; Malik, FI; McMurray, JJV; Solomon, SD; Teerlink, JR; Zhang, H	1
Abbasi, S; Biering-Sørensen, T; Claggett, B; Felker, GM; Kurtz, CE; Liu, J; Malik, FI; McMurray, JJV; Minamisawa, M; Solomon, SD; Teerlink, JR	1
Abbasi, SA; Adams, KF; Anand, I; Arias-Mendoza, A; Biering-Sørensen, T; Böhm, M; Bonderman, D; Cleland, JGF; Corbalan, R; Crespo-Leiro, MG; Dahlström, U; Diaz, R; Echeverria, LE; Fang, JC; Felker, GM; Filippatos, G; Fonseca, C; Goncalvesova, E; Goudev, AR; Honarpour, N; Howlett, JG; Kurtz, CE; Lanfear, DE; Legg, JC; Li, J; Lund, M; Macdonald, P; Malik, FI; Mareev, V; McMurray, JJV; Metra, M; Momomura, SI; O'Meara, E; Parkhomenko, A; Ponikowski, P; Ramires, FJA; Serpytis, P; Sharpsten, L; Sliwa, K; Solomon, SD; Spinar, J; Suter, TM; Teerlink, JR; Tomcsanyi, J; Vandekerckhove, H; Varin, C; Vinereanu, D; Voors, AA; Yilmaz, MB; Zannad, F	1
Swedberg, K	1
Carlo, P; Massimo, V	1
Lam, CSP; Teramoto, K; Tromp, J	1
Atherton, JL; Barua, B; Forgacs, E; Goldman, YE; Ostap, EM; Shuman, H; Snoberger, A; Winkelmann, DA	1
Doh, CY; Dominic, KL; Holmes, JB; Madugula, N; Mamidi, R; Stelzer, JE	1
Ali, A; Ikram, S; Shah, SR	1
Biering-Sørensen, T; Claggett, B; Felker, GM; Honarpour, N; Kurtz, CE; Legg, JC; Liu, J; Malik, FI; McMurray, JJV; Minamisawa, M; Papolos, AI; Solomon, SD; Teerlink, JR	1
Kumar, P; Palaian, S; Prabhu, MM	1
Beard, N; Chan, W; Cheesman, E; Dashwood, A; Haqqani, H; Hay, K; Molenaar, P; Spratt, M; Wong, YW	1
Arimura, Z; Fang, M; Gao, B; Qu, Y; Vargas, HM	1
Felker, GM; Mann, DL	1
Campbell, SG; Sewanan, LR; Shen, S	1
Komamura, K	1
Bonapace, S; Molon, G	1
Bellumkonda, L	1
Felker, GM; McMurray, JJV; Teerlink, JR	1
Dutta, S; Lee, E; Mackowski, M; Trivedi, A; Wahlstrom, J	1
Abbasi, SA; Biering-Sørensen, T; Böhm, M; Bonderman, D; Claggett, BL; Diaz, R; Fang, JC; Felker, GM; Flores-Arredondo, JH; Heitner, SB; Kupfer, S; Lanfear, DE; Lund, M; Malik, FI; McMurray, JJV; Metra, M; Momomura, SI; O'Meara, E; Ponikowski, P; Solomon, SD; Spinar, J; Teerlink, JR	1
Ferreira, JP	1
Gronda, E; Iacoviello, M; Palazzuoli, A	1
Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Mackowski, M; Oberoi, RK; Simiens, MA; Terminello, B; Trivedi, A; Zhang, H	1
Campbell, SG; Jacoby, DL; Sewanan, LR; Shen, S	1
Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Oberoi, RK; Spring, M; Trivedi, A; Zhang, H	1
Abbasi, S; Dutta, S; Flach, S; Hutton, S; Jafarinasabian, P; Lee, E; Mackowski, M; Oberoi, RK; Trivedi, A; Zhang, H	1
Bhatia, A; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Mackowski, M; Terminello, B; Trivedi, A; Zhang, H	1
Abbasi, S; Brooks, A; Darpo, B; Dutta, S; Flach, S; Hsu, CP; Israel, S; Jafarinasabian, P; Lee, E; Terminello, B; Trivedi, A; Xue, H; Zhang, H	1
Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Malik, FI; Trivedi, A; Zhang, H	1
Chen, CH; Chen, YJ; Cheng, HM; Chiang, CE; Chien, CS	1
Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Lee, E; Sohn, W; Terminello, B; Trivedi, A; Zhang, H	1
Annoni, F; El Oumeiri, B; Herpain, A; Hubesch, G; Jespers, P; Mc Entee, K; Stefanidis, C; van de Borne, P; Vanden Eynden, F	1
Abbasi, S; Aoki, M; Dutta, S; Hutton, S; Lee, E; Mackowski, M; Malik, FI; Trivedi, A	1
Abbasi, S; Dutta, S; Flach, S; Jafarinasabian, P; Kulkarni, P; Lee, E; Sohn, W; Spring, M; Trivedi, A; Wahlstrom, J; Zhang, H	1
Alothman, AA; Arumugam, R; Atallah, MM; Bagheri, D; Cui, M; El-Sabbagh, NM; El-Sayed, NS; Ghafarifarsani, H; Ghetas, HA; Hedayati, SA; Hosseini Shekarabi, SP; Inoue, Y; Khalil, RH; Khallaf, MM; Kuroda, Y; Kuznetsov, D; Lee, J; Lookin, O; Nam, YW; Nemoto, H; Nguyen, M; Noda, M; Numaguchi, R; Orfali, R; Priscillal, IJD; Protsenko, Y; Rahman, MA; Shahbazi Naserabad, S; Shakweer, MS; Sheikh Veisi, R; Takahashi, K; Tanaka, C; Wada, K; Wang, SF; Yang, G; Yoshino, K; Zhang, M	1
Kravchenko, I; Medentseva, O; Rudyk, I	1
Abbasi, S; Dutta, S; Flach, S; Hsu, CP; Hutton, S; Jafarinasabian, P; Lee, E; Sohn, W; Trivedi, A; Zhang, H	1
Abbasi, SA; Anand, I; Claggett, B; Crespo-Leiro, MG; Dahlström, U; Diaz, R; Felker, GM; Goncalvesova, E; Heitner, SB; Howlett, JG; Hucko, T; Kupfer, S; MacDonald, P; Malik, FI; McMurray, JJV; Metra, M; Parkhomenko, A; Solomon, SD; Teerlink, JR; Tomcsányi, J	1
Acero, JC; Butova, X; Gurev, V; Khamzin, S; Khokhlova, A; Kozloski, J; Myachina, T; Parikh, J; Rumbell, T; Solovyova, O	1
Ahamadi, M; Chen, PW; Dutta, S; Lee, E; Trivedi, A	1
Christ, T; Eschenhagen, T; Hansen, A; Pietsch, N; Rhoden, A; Schulze, T	1
Chen, WJ; Huang, CH; Tsai, MS; Wu, SN	1
Claggett, BL; Corbalan, R; Diaz, R; Felker, GM; Filippatos, G; Goudev, AR; Heitner, SB; Kupfer, S; Malik, FI; Mareev, V; McMurray, JJV; Metra, M; Miao, ZM; Serpytis, P; Solomon, SD; Suter, T; Teerlink, JR; Yilmaz, MB; Zannad, F	1
Rienstra, M; van der Meer, P; van Veldhuisen, DJ	1
Böhm, M; Cohen-Solal, A; Divanji, PH; Docherty, KF; Ezekowitz, JA; Felker, GM; Heitner, SB; Kupfer, S; Lewis, GD; Lopes, RD; Malik, FI; Meng, L; Metra, M; Teerlink, JR; Voors, AA; Whellan, DJ; Wohltman, A	1
Drazner, MH	1
Barge-Caballero, E; Crespo-Leiro, MG; McDonagh, TA	1
Hernandez, AF	1
Adams, KF; Anand, I; Badat, A; Burgess, L; Claggett, BL; Diaz, R; Fang, JC; Felker, GM; Gorodeski, EZ; Heitner, SB; Kupfer, S; Lanfear, DE; Malik, FI; McMurray, JJV; Metra, M; Miao, ZM; Njoroge, JN; Ramires, F; Sliwa-Hahnle, K; Solomon, S; Teerlink, JR; Williams, C	1
Albert, NM; Alhanti, B; Allen, LA; DeVore, AD; Divanji, PH; Felker, GM; Fonarow, GC; Greene, SJ; Harrington, J; Heitner, SB; Sun, JL; Yancy, CW	1

Reviews

21 review(s) available for urea and omecamtiv mecarbil

Article	Year
A novel approach to improve cardiac performance: cardiac myosin activators. Heart failure reviews, 2009, Volume: 14, Issue:4 Topics: Animals; Cardiac Myosins; Cardiotonic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Heart Failure; Humans; Myocardial Contraction; Urea; Ventricular Function, Left	2009
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart failure reviews, 2009, Volume: 14, Issue:4 Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents	2009
Cardiovascular pharmacology: an update. Anesthesiology clinics, 2010, Volume: 28, Issue:4 Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Diastole; Heart Failure; Humans; Hydrazones; Muscle Contraction; Myofibrils; Natriuretic Peptide, Brain; Nicardipine; Pyridazines; Pyridines; Sarcomeres; Simendan; Urea	2010
Cardiac myosin activation part 1: from concept to clinic. Journal of molecular and cellular cardiology, 2011, Volume: 51, Issue:4 Topics: Animals; Cardiotonic Agents; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Heart Failure, Systolic; Humans; Myocardial Contraction; Myocardium; Myosins; Small Molecule Libraries; Urea	2011
Novel pharmacologic therapies in development for acute decompensated heart failure. Current cardiology reports, 2013, Volume: 15, Issue:2 Topics: Acute Disease; Atrial Natriuretic Factor; Diuretics; Heart Failure; Humans; Peptide Fragments; Relaxin; Urea; Vasodilator Agents	2013
Acute decompensated heart failure: update on new and emerging evidence and directions for future research. Journal of cardiac failure, 2013, Volume: 19, Issue:6 Topics: Adrenomedullin; Atrial Natriuretic Factor; Biomarkers; Blood Pressure Monitoring, Ambulatory; Cardiotonic Agents; Clinical Trials as Topic; Diet, Sodium-Restricted; Diuretics; Dopamine; Dose-Response Relationship, Drug; Dyspnea; Glycopeptides; Heart Failure; Hemofiltration; Hospitalization; Humans; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Peptide Fragments; Prognosis; Protein Precursors; Quality of Health Care; Relaxin; Risk Assessment; Saline Solution, Hypertonic; Urea; Vasodilator Agents; Xanthines	2013
An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:4 Topics: Amides; Benzoates; Cardiac Resynchronization Therapy; Cardiotonic Agents; Fumarates; Heart Failure; Humans; Recombinant Proteins; Relaxin; Ultrafiltration; Urea	2014
Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European journal of heart failure, 2014, Volume: 16, Issue:5 Topics: Cell Survival; Cyclosporine; Drugs, Investigational; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardial Contraction; Myocytes, Cardiac; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Translational Research, Biomedical; Urea; Ventricular Remodeling	2014
Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert opinion on investigational drugs, 2016, Volume: 25, Issue:1 Topics: Animals; Cardiac Myosins; Cardiotonic Agents; Disease Models, Animal; Heart Failure, Systolic; Humans; Myocardial Contraction; Randomized Controlled Trials as Topic; Urea	2016
Manufacturing of [(14)C]-Labeled Drug Substance and Drug Product Utilized in Clinical Research: A Case Study of Omecamtiv Mecarbil. Current pharmaceutical design, 2016, Volume: 22, Issue:5 Topics: Absorption, Physiological; Carbon Radioisotopes; Clinical Trials as Topic; Drug Compounding; Drug Liberation; Humans; Urea	2016
Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? Current cardiology reports, 2016, Volume: 18, Issue:10 Topics: Animals; Cardiac Myosins; Cardiotonic Agents; Disease Models, Animal; Heart Failure, Systolic; Humans; Myocardial Contraction; Randomized Controlled Trials as Topic; Stroke Volume; Urea	2016
Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. Handbook of experimental pharmacology, 2017, Volume: 243 Topics: Animals; Cardiac Myosins; Cardiotonic Agents; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Humans; Myocardial Contraction; Stroke Volume; Urea	2017
Pharmacologic Management for Heart Failure and Emerging Therapies. Current cardiology reports, 2017, 08-24, Volume: 19, Issue:10 Topics: Aminobutyrates; Benzazepines; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Glucosides; Heart Failure; Humans; Ivabradine; Neuregulin-1; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Urea; Valsartan	2017
Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results. Current medicinal chemistry, 2018, Volume: 25, Issue:15 Topics: Animals; Cardiotonic Agents; Dose-Response Relationship, Drug; Enzyme Activators; Heart Failure; Humans; Myocardial Contraction; Myosins; Oxygen Consumption; Ryanodine Receptor Calcium Release Channel; Urea	2018
Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies. Annual review of genomics and human genetics, 2019, 08-31, Volume: 20 Topics: Benzylamines; Cardiac Myosins; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Carrier Proteins; Connectin; Gene Expression; Humans; Mutation; Myocardial Contraction; Myocardium; Myosin Heavy Chains; RNA-Binding Proteins; Sarcomeres; Troponin T; Uracil; Urea	2019
New drugs: big changes in conservative heart failure therapy? European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2019, 06-01, Volume: 55, Issue:Suppl 1 Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Enzyme Activators; Glucosides; Heart Failure; Humans; Hyperkalemia; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Iron; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea	2019
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC. Heart failure, 2020, Volume: 8, Issue:4 Topics: Heart Failure; Humans; Myocardial Contraction; Randomized Controlled Trials as Topic; Stroke Volume; Urea; Ventricular Function, Left	2020
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure. Journal of cardiovascular pharmacology, 2021, 01-01, Volume: 77, Issue:1 Topics: Animals; Cardiac Myosins; Cardiotonic Agents; Heart Failure, Systolic; Humans; Myocardium; Recovery of Function; Signal Transduction; Stroke Volume; Treatment Outcome; Urea; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling	2021
Mechanisms and Models in Heart Failure: A Translational Approach. Circulation research, 2021, 05-14, Volume: 128, Issue:10 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Development; Enzyme Activators; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Models, Biological; Natriuretic Peptides; Neprilysin; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Soluble Guanylyl Cyclase; Stroke Volume; Urea; Valsartan; Ventricular Remodeling	2021
Recent advances in pharmacological treatment of heart failure. European journal of clinical investigation, 2021, Volume: 51, Issue:11 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Drug Combinations; Ferric Compounds; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Iron Deficiencies; Maltose; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea; Valsartan; Vasodilator Agents; Ventricular Remodeling	2021
From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin. International journal of molecular sciences, 2021, Jun-21, Volume: 22, Issue:12 Topics: Benzylamines; Cardiac Myosins; Heart Failure; Humans; Molecular Targeted Therapy; Myocytes, Cardiac; Uracil; Urea	2021

Trials

22 trial(s) available for urea and omecamtiv mecarbil

Article	Year
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet (London, England), 2011, Aug-20, Volume: 378, Issue:9792 Topics: Adult; Cardiac Myosins; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Myocardial Contraction; Stroke Volume; Systole; Urea; Ventricular Function, Left; Young Adult	2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet (London, England), 2011, Aug-20, Volume: 378, Issue:9792 Topics: Blood Pressure; Cardiac Myosins; Cross-Over Studies; Double-Blind Method; Echocardiography; Female; Heart Failure, Systolic; Humans; Infusions, Intravenous; Male; Stroke Volume; Systole; Urea; Ventricular Dysfunction, Left	2011
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC. Heart failure, 2015, Volume: 3, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angina Pectoris; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Exercise; Exercise Test; Female; Follow-Up Studies; Georgia (Republic); Humans; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Retrospective Studies; Russia; Treatment Outcome; Urea	2015
Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. Journal of clinical pharmacology, 2015, Volume: 55, Issue:11 Topics: Adult; Aged; Cardiac Myosins; Cross-Over Studies; Double-Blind Method; Female; Healthy Volunteers; Heart Failure; Humans; Male; Middle Aged; Models, Biological; Stroke Volume; Systole; Urea; Young Adult	2015
Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. International journal of clinical pharmacology and therapeutics, 2016, Volume: 54, Issue:3 Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Urea	2016
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Journal of the American College of Cardiology, 2016, Mar-29, Volume: 67, Issue:12 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Prospective Studies; Stroke Volume; Treatment Outcome; Troponin; Urea; Ventricular Function, Left; Young Adult	2016
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Administration, Oral; Cardiac Myosins; Dose-Response Relationship, Drug; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Systole; Urea; Ventricular Function, Left; Ventricular Remodeling	2016
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. European journal of heart failure, 2020, Volume: 22, Issue:11 Topics: Aged; Female; Heart Failure; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke Volume; Urea; Ventricular Function, Left	2020
Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. Circulation. Heart failure, 2020, Volume: 13, Issue:12 Topics: Aged; Biomarkers; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Severity of Illness Index; Stroke Volume; Surveys and Questionnaires; Urea; Ventricular Dysfunction, Left	2020
Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. Circulation. Heart failure, 2020, Volume: 13, Issue:12 Topics: Aged; Biomarkers; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Systole; Urea; Ventricular Dysfunction, Left; Ventricular Remodeling	2020
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. The New England journal of medicine, 2021, 01-14, Volume: 384, Issue:2 Topics: Aged; Aged, 80 and over; Cardiac Myosins; Cardiotonic Agents; Cardiovascular Diseases; Female; Heart Failure, Systolic; Humans; Male; Middle Aged; Myocardial Contraction; Stroke Volume; Urea	2021
Pharmacokinetics, Disposition, and Biotransformation of [ Drug metabolism and disposition: the biological fate of chemicals, 2021, Volume: 49, Issue:8 Topics: Administration, Intravenous; Administration, Oral; Adult; Biological Availability; Biotransformation; Cardiovascular Agents; Cytochrome P450 Family 4; Healthy Volunteers; Heart Failure; Hepatobiliary Elimination; Humans; Infusions, Intravenous; Intestinal Absorption; Male; Renal Elimination; Urea	2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. Journal of the American College of Cardiology, 2021, 07-13, Volume: 78, Issue:2 Topics: Aged; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Treatment Outcome; Urea	2021
Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator. Biopharmaceutics & drug disposition, 2021, Volume: 42, Issue:7 Topics: Administration, Oral; Adult; Area Under Curve; Cardiac Myosins; Cross-Over Studies; Delayed-Action Preparations; Drug Substitution; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Tablets; Therapeutic Equivalency; Urea	2021
Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects. Clinical drug investigation, 2021, Volume: 41, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Cross-Over Studies; Delayed-Action Preparations; Drug Compounding; Female; Half-Life; Healthy Volunteers; Heart Failure; Humans; Male; Middle Aged; Myalgia; Tablets; Urea; Young Adult	2021
Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations. British journal of clinical pharmacology, 2022, Volume: 88, Issue:1 Topics: Cross-Over Studies; Double-Blind Method; Electrocardiography; Fluoroquinolones; Heart Rate; Humans; Moxifloxacin; Urea	2022
Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects. European journal of drug metabolism and pharmacokinetics, 2021, Volume: 46, Issue:6 Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Biological Availability; Female; Half-Life; Healthy Volunteers; Humans; Japan; Male; Tablets; Urea	2021
JTCVS open, 2021, Volume: 8 Topics: Aeromonas hydrophila; Animal Feed; Animals; Antioxidants; Cadmium Chloride; Calmodulin; Cardiotonic Agents; Carps; Cichlids; Diet; Dietary Supplements; Dose-Response Relationship, Drug; Fish Diseases; Heart; Heart Failure; Lacticaseibacillus casei; Liver; Magnetic Iron Oxide Nanoparticles; Male; Monocrotaline; Mutagenesis, Site-Directed; Myocardial Contraction; Oxidative Stress; Potassium Channels, Calcium-Activated; Rats; Rats, Wistar; Urea; Withania	2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. JAMA cardiology, 2022, 01-01, Volume: 7, Issue:1 Topics: Blood Pressure; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Patient Acuity; Retrospective Studies; Stroke Volume; Treatment Outcome; Urea; Ventricular Function, Left	2022
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European heart journal, 2022, 06-14, Volume: 43, Issue:23 Topics: Atrial Fibrillation; Atrial Flutter; Digoxin; Heart Failure; Humans; Quality of Life; Stroke Volume; Urea; Ventricular Function, Left	2022
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. JAMA, 2022, 07-19, Volume: 328, Issue:3 Topics: Aged; Cardiovascular Agents; Chronic Disease; Double-Blind Method; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Urea; Ventricular Dysfunction, Left; Ventricular Function, Left	2022
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF. JACC. Heart failure, 2023, Volume: 11, Issue:5 Topics: Heart Failure; Humans; Stroke Volume; Urea; Ventricular Function, Left	2023

Other Studies

82 other study(ies) available for urea and omecamtiv mecarbil

Article	Year
Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circulation. Heart failure, 2010, Volume: 3, Issue:4 Topics: Analysis of Variance; Animals; Cardiac Myosins; Consciousness; Disease Models, Animal; Dobutamine; Dogs; Drug Administration Schedule; Female; Heart Failure, Systolic; Heart Function Tests; Infusions, Intravenous; Male; Myocardial Contraction; Myocardial Infarction; Oxygen Consumption; Probability; Random Allocation; Stroke Volume; Treatment Outcome; Urea; Ventricular Function, Left; Ventricular Remodeling	2010
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? Current heart failure reports, 2010, Volume: 7, Issue:3 Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobutamine; Etiocholanolone; Genetic Therapy; Heart Failure; Humans; Hydrazones; Pyridazines; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Potassium-Exchanging ATPase; Urea	2010
Medicine. Chemically tuned myosin motors. Science (New York, N.Y.), 2011, Mar-18, Volume: 331, Issue:6023 Topics: Actins; Adenosine Diphosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Cardiac Myosins; Heart Failure, Systolic; Humans; Myocardial Contraction; Phosphates; Protein Binding; Protein Isoforms; Urea	2011
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (New York, N.Y.), 2011, Mar-18, Volume: 331, Issue:6023 Topics: Actin Cytoskeleton; Actins; Adenosine Triphosphatases; Adenosine Triphosphate; Adrenergic beta-Agonists; Allosteric Regulation; Animals; Binding Sites; Calcium; Cardiac Myosins; Cardiac Output; Dogs; Female; Heart Failure, Systolic; Isoproterenol; Male; Myocardial Contraction; Myocytes, Cardiac; Phosphates; Protein Binding; Protein Conformation; Protein Isoforms; Rats; Rats, Sprague-Dawley; Urea; Ventricular Function, Left	2011
Translational medicine: to the rescue of the failing heart. Nature, 2011, May-05, Volume: 473, Issue:7345 Topics: Cardiotonic Agents; Heart; Heart Failure; Humans; Translational Research, Biomedical; Urea	2011
Cardiac myosin activation: will theory and practice coincide? Lancet (London, England), 2011, Aug-20, Volume: 378, Issue:9792 Topics: Cardiac Myosins; Heart Failure, Systolic; Humans; Urea	2011
Omecamtiv mecarbil: a promising new drug in systolic heart failure. European journal of heart failure, 2012, Volume: 14, Issue:3 Topics: Heart Failure, Systolic; Humans; Muscle Cells; Myosins; Urea; Ventricular Function, Left	2012
Synthesis and 18F-labeling of the analogues of Omecamtiv Mecarbil as a potential cardiac myosin imaging agent with PET. Nuclear medicine and biology, 2013, Volume: 40, Issue:5 Topics: Animals; Cattle; Chemical Phenomena; Chemistry Techniques, Synthetic; Drug Stability; Fluorine Radioisotopes; Isotope Labeling; Mice; Myocardium; Myosins; Positron-Emission Tomography; Radiochemistry; Substrate Specificity; Urea	2013
Drug discovery and development for acute heart failure drugs: are expectations too high? International journal of cardiology, 2014, Mar-01, Volume: 172, Issue:1 Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Drug Discovery; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Urea	2014
Analytical comparison of natural and pharmaceutical ventricular myosin activators. Biochemistry, 2014, Aug-19, Volume: 53, Issue:32 Topics: Adenosine Triphosphatases; Animals; Muscle, Skeletal; Myocardium; Quantum Dots; Rabbits; Streptavidin; Urea; Ventricular Myosins	2014
Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin. Biochemistry, 2015, Mar-17, Volume: 54, Issue:10 Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cardiac Myosins; Kinetics; Myocardial Contraction; Myocardium; Swine; Urea	2015
Myosin VI deafness mutation prevents the initiation of processive runs on actin. Proceedings of the National Academy of Sciences of the United States of America, 2015, Mar-17, Volume: 112, Issue:11 Topics: Actins; Adenosine Diphosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Biomechanical Phenomena; Deafness; Humans; Kinetics; Mice; Models, Biological; Models, Molecular; Mutant Proteins; Mutation; Myosin Heavy Chains; Protein Multimerization; Protein Structure, Tertiary; Sus scrofa; Urea	2015
Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector. Cell reports, 2015, May-12, Volume: 11, Issue:6 Topics: Actin Cytoskeleton; Actins; Adenosine Triphosphatases; Animals; Biomechanical Phenomena; Cardiomyopathies; Cattle; Humans; Mice; Models, Biological; Models, Molecular; Mutation; Small Molecule Libraries; Software; Statistics as Topic; Urea; Utrophin; Ventricular Myosins	2015
Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity. Circulation. Heart failure, 2015, Volume: 8, Issue:4 Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Energy Metabolism; Enzyme Activation; Enzyme Activators; Female; Heart Failure; Male; Mice; Myocardial Contraction; Myocardial Infarction; Myocardium; Myosins; Oxygen Consumption; Stroke Volume; Sus scrofa; Urea; Ventricular Dysfunction, Left; Ventricular Function, Left	2015
Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K. Journal of cardiovascular pharmacology, 2015, Volume: 66, Issue:4 Topics: Animals; Calcium; Cardiac Myosins; Cardiomyopathy, Dilated; Disease Models, Animal; Mice, Transgenic; Mutation; Myofibrils; Tropomyosin; Urea	2015
Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C. Journal of molecular and cellular cardiology, 2015, Volume: 85 Topics: Animals; Calcium; Carrier Proteins; Enzyme Activators; Female; Humans; Kinetics; Male; Mice, 129 Strain; Mice, Knockout; Myocardial Contraction; Myocardium; Myosins; Phosphorylation; Protein Processing, Post-Translational; Sarcomeres; Urea	2015
Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity. Nature communications, 2015, Aug-06, Volume: 6 Topics: Allosteric Regulation; Allosteric Site; Animals; Cardiac Myosins; Cell Line; Green Fluorescent Proteins; Humans; Mice; Protein Structure, Tertiary; Urea	2015
A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation. American journal of physiology. Heart and circulatory physiology, 2016, 07-01, Volume: 311, Issue:1 Topics: Actins; Animals; Animals, Newborn; Cardiac Myosins; Cardiotonic Agents; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Genotype; Humans; Induced Pluripotent Stem Cells; Myocardial Contraction; Myocytes, Cardiac; Phenotype; Point Mutation; Rats, Sprague-Dawley; Sarcomeres; Time Factors; Troponin T; Urea	2016
Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. Health and quality of life outcomes, 2016, Sep-15, Volume: 14, Issue:1 Topics: Aged; Aged, 80 and over; Cardiac Myosins; Cardiovascular Agents; Clinical Trials as Topic; Dizziness; Dyspnea; Edema; Fatigue; Female; Focus Groups; Heart Failure; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Qualitative Research; Quality of Life; Sleep Initiation and Maintenance Disorders; United States; United States Food and Drug Administration; Urea	2016
Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2016, Volume: 67, Issue:4 Topics: Action Potentials; Animals; Dogs; Female; Heart Ventricles; Male; Myocytes, Cardiac; Myosins; Patch-Clamp Techniques; Urea	2016
Heart failure: Phase II trial results of omecamtiv mecarbil. Nature reviews. Cardiology, 2017, Volume: 14, Issue:2 Topics: Cardiotonic Agents; Clinical Trials, Phase II as Topic; Heart Failure, Systolic; Humans; Randomized Controlled Trials as Topic; Urea	2017
Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle. The Journal of biological chemistry, 2017, 03-03, Volume: 292, Issue:9 Topics: Actins; Actomyosin; Adenosine Diphosphate; Animals; Calcium; Dose-Response Relationship, Drug; Humans; Kinetics; Mass Spectrometry; Mice; Myocardium; Myosins; Protein Domains; Recombinant Proteins; Stress, Mechanical; Urea; Ventricular Myosins	2017
Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke. Proceedings of the National Academy of Sciences of the United States of America, 2017, 03-07, Volume: 114, Issue:10 Topics: Animals; Biosensing Techniques; Cardiac Myosins; Cardiovascular Agents; Cattle; Chickens; Heart Failure; Humans; Kinetics; Myocardial Contraction; Myocardium; Myosins; Phosphates; Rabbits; Urea	2017
Omecamtiv mecarbil activates ryanodine receptors from canine cardiac but not skeletal muscle. European journal of pharmacology, 2017, Aug-15, Volume: 809 Topics: Animals; Dogs; Dose-Response Relationship, Drug; Female; Heart; Male; Muscle, Skeletal; Myocardium; Rabbits; Ryanodine Receptor Calcium Release Channel; Urea	2017
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nature communications, 2017, 08-04, Volume: 8, Issue:1 Topics: Animals; Binding Sites; Cardiac Myosins; Cattle; Crystallization; Protein Conformation; Urea	2017
Omecamtiv Mecarbil Abolishes Length-Mediated Increase in Guinea Pig Cardiac Myofiber Ca Biophysical journal, 2017, Aug-22, Volume: 113, Issue:4 Topics: Animals; Biomechanical Phenomena; Calcium; Dose-Response Relationship, Drug; Guinea Pigs; Myocardial Contraction; Phosphorylation; Sarcomeres; Urea	2017
Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes. Naunyn-Schmiedeberg's archives of pharmacology, 2017, Volume: 390, Issue:12 Topics: Action Potentials; Animals; Calcium Signaling; Cell Size; Diastole; Dogs; Female; Heart Ventricles; Male; Myocardial Contraction; Myocytes, Cardiac; Myosins; Systole; Urea	2017
Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament. The Journal of physiology, 2018, 01-01, Volume: 596, Issue:1 Topics: Actin Cytoskeleton; Animals; Calcium; Cardiac Myosins; Heterocyclic Compounds, 4 or More Rings; Male; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Rats; Rats, Wistar; Signal Transduction; Urea	2018
Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil. PLoS computational biology, 2017, Volume: 13, Issue:11 Topics: Allosteric Regulation; Allosteric Site; Cardiac Myosins; Crystallography, X-Ray; Humans; Molecular Dynamics Simulation; Protein Conformation; Urea	2017
Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats. BMC cardiovascular disorders, 2018, 05-21, Volume: 18, Issue:1 Topics: Animals; Aortic Valve; Aortic Valve Insufficiency; Cardiac Myosins; Cardiovascular Agents; Chronic Disease; Disease Models, Animal; Echocardiography, Doppler; Hemodynamics; Infusions, Intravenous; Male; Rats, Wistar; Recovery of Function; Severity of Illness Index; Stroke Volume; Urea; Ventricular Function, Left	2018
Perspectives of a myosin motor activator agent with increased selectivity. Canadian journal of physiology and pharmacology, 2018, Volume: 96, Issue:7 Topics: Animals; Cardiac Myosins; Clinical Trials, Phase III as Topic; Computer Simulation; Dogs; Heart Failure; Humans; Molecular Docking Simulation; Myosin Heavy Chains; Protein Structure, Tertiary; Ryanodine Receptor Calcium Release Channel; Software; Structure-Activity Relationship; Urea	2018
Controlling load-dependent kinetics of β-cardiac myosin at the single-molecule level. Nature structural & molecular biology, 2018, Volume: 25, Issue:6 Topics: Actins; Animals; Cattle; Dose-Response Relationship, Drug; Heart Ventricles; Humans; Kinetics; Mutation; Myocardial Contraction; Urea; Ventricular Myosins	2018
Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke. Nature communications, 2018, 09-21, Volume: 9, Issue:1 Topics: Adenosine Triphosphate; Animals; Cardiotonic Agents; Cell Line; Drug Evaluation, Preclinical; Mice; Monte Carlo Method; Myosins; Optical Tweezers; Swine; Urea	2018
Treatments targeting inotropy. European heart journal, 2019, 11-21, Volume: 40, Issue:44 Topics: Acute Disease; Animals; Antioxidants; Calcium; Cardiotonic Agents; Case-Control Studies; Catecholamines; Clinical Trials as Topic; Diastole; Dobutamine; Dogs; Energy Metabolism; Excitation Contraction Coupling; Heart Failure; Humans; Mitochondria; Models, Animal; Myocardial Contraction; Nitrogen Oxides; Oxidation-Reduction; Phosphodiesterase Inhibitors; Placebos; Receptors, Adrenergic; Sarcomeres; Shock, Cardiogenic; Simendan; Swine; Systole; Urea	2019
Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. Physiological reports, 2018, Volume: 6, Issue:19 Topics: Animals; Cardiotonic Agents; Cardiovascular Agents; Diastole; Dobutamine; Drug Therapy, Combination; Heart Failure; Ivabradine; Male; Myocardial Ischemia; Swine; Treatment Outcome; Urea	2018
SarcTrack. Circulation research, 2019, 04-12, Volume: 124, Issue:8 Topics: Algorithms; Benzylamines; Cardiovascular Agents; Carrier Proteins; Clustered Regularly Interspaced Short Palindromic Repeats; Computer-Aided Design; Fluorescence; Humans; Induced Pluripotent Stem Cells; Microscopy, Atomic Force; Myocardial Contraction; Myocytes, Cardiac; Myosins; Propranolol; Sarcomeres; Software; Uracil; Urea; Verapamil; Video Recording	2019
Omecamtiv Mecarbil Slows Myosin Kinetics in Skinned Rat Myocardium at Physiological Temperature. Biophysical journal, 2019, 06-04, Volume: 116, Issue:11 Topics: Animals; Calcium; Kinetics; Male; Myocardium; Myosins; Rats; Rats, Sprague-Dawley; Temperature; Urea	2019
Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil. The Journal of biological chemistry, 2019, 11-15, Volume: 294, Issue:46 Topics: Actin Cytoskeleton; Actins; Actomyosin; Adenosine Triphosphatases; Cardiomyopathy, Dilated; Heart Failure; Humans; Kinetics; Motor Activity; Mutation; Myocardial Contraction; Protein Domains; Urea; Ventricular Myosins	2019
Combined Therapy With Dobutamine and Omecamtiv Mecarbil in Pigs With Ischemic Acute Heart Failure Is Attributed to the Effect of Dobutamine. Journal of cardiovascular pharmacology and therapeutics, 2020, Volume: 25, Issue:3 Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Drug Therapy, Combination; Energy Metabolism; Heart Failure; Male; Myocardial Contraction; Myocardial Ischemia; Oxygen Consumption; Sus scrofa; Urea; Ventricular Function, Left	2020
Targeted and Controlled Drug Delivery to a Rat Model of Heart Failure Through a Magnetic Nanocomposite. Annals of biomedical engineering, 2020, Volume: 48, Issue:2 Topics: Animals; Cell Line; Disease Models, Animal; Drug Delivery Systems; Heart Failure; Magnetic Fields; Male; Myocardium; Nanocomposites; Rats; Rats, Wistar; Urea	2020
Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy. PloS one, 2019, Volume: 14, Issue:11 Topics: Animals; Calcium; Disease Models, Animal; Mice; Mice, Knockout; Muscle Contraction; Muscle Fibers, Skeletal; Muscle Proteins; Myopathies, Nemaline; Urea	2019
Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes. European heart journal, 2019, 11-21, Volume: 40, Issue:44 Topics: Acute Disease; Anemia, Iron-Deficiency; Anticoagulants; Cardiotonic Agents; Case-Control Studies; Diuretics; Factor Xa Inhibitors; Heart Aneurysm; Heart Failure; Humans; Hypertension; Iron; Myocardial Infarction; Pacemaker, Artificial; Percutaneous Coronary Intervention; Placebos; Portraits as Topic; Rivaroxaban; Stroke; Stroke Volume; Thrombosis; Urea	2019
Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency. Stem cell reports, 2020, 02-11, Volume: 14, Issue:2 Topics: Artifacts; Biomechanical Phenomena; Calcium Signaling; Fluorescence; Heart; Humans; Motion; Myocardial Contraction; Tissue Engineering; Urea	2020
Myosin from the ventricle is more sensitive to omecamtiv mecarbil than myosin from the atrium. Biochemical and biophysical research communications, 2020, 08-06, Volume: 528, Issue:4 Topics: Actins; Animals; Heart Atria; Heart Ventricles; Myocardial Contraction; Myosins; Protein Interaction Maps; Swine; Urea	2020
The Galaxy of Cytoskeletal Modulation in the Universe of Heart Failure Therapeutics. JACC. Heart failure, 2020, Volume: 8, Issue:7 Topics: Chronic Disease; Heart Failure; Humans; Urea	2020
Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil. Nature communications, 2020, 07-07, Volume: 11, Issue:1 Topics: Adenosine Triphosphatases; Animals; Calcium; Cardiac Myosins; Drug Synergism; Male; Muscle, Skeletal; Myocardial Contraction; Myosins; Phosphates; Rabbits; Sarcomeres; Stress, Mechanical; Urea	2020
Single-Cell Mechanical Analysis of Human Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Testing and Pathophysiological Studies. Stem cell reports, 2020, 09-08, Volume: 15, Issue:3 Topics: Biomechanical Phenomena; Cell Differentiation; Cell Line; Cell Shape; Doxorubicin; Drug Evaluation, Preclinical; Humans; Myocardial Contraction; Myocytes, Cardiac; Pluripotent Stem Cells; Single-Cell Analysis; Urea	2020
Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model. Pharmacology research & perspectives, 2020, Volume: 8, Issue:5 Topics: Animals; Calcium Signaling; Dogs; Dose-Response Relationship, Drug; Fura-2; Heart Ventricles; Humans; Isoproterenol; Male; Models, Animal; Muscle Cells; Muscle Contraction; Sarcomeres; Urea	2020
Stimulation of Contractility in Systolic Heart Failure. The New England journal of medicine, 2021, 01-14, Volume: 384, Issue:2 Topics: Heart Failure; Heart Failure, Systolic; Humans; Urea	2021
Truly galactic? European heart journal, 2021, 01-21, Volume: 42, Issue:4 Topics: Cardiac Myosins; Heart Failure, Systolic; Humans; Urea	2021
Heart failure or heart success? Cardiovascular research, 2021, 02-22, Volume: 117, Issue:3 Topics: Cardiovascular Agents; Evidence-Based Medicine; Ferric Compounds; Glycosides; Heart Failure, Systolic; Hospitalization; Humans; Maltose; Randomized Controlled Trials as Topic; Recovery of Function; Research Design; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Urea; Ventricular Function, Left	2021
Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil. eLife, 2021, 02-19, Volume: 10 Topics: Cardiomegaly; Cardiotonic Agents; Heart Failure; Humans; Mutation; Urea; Ventricular Myosins	2021
cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation. The Journal of general physiology, 2021, 07-05, Volume: 153, Issue:7 Topics: Animals; Humans; Mice; Myocardial Contraction; Myocardium; Phosphorylation; Urea	2021
Omecamtiv Mecarbil use in systolic heart failure- Results of the GALACTIC-HF trial. Expert review of clinical pharmacology, 2021, Volume: 14, Issue:4 Topics: Cardiotonic Agents; Heart Failure, Systolic; Humans; Randomized Controlled Trials as Topic; Urea	2021
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). European journal of heart failure, 2021, Volume: 23, Issue:6 Topics: Cardiac Myosins; Heart Failure; Heart Failure, Systolic; Humans; Stroke Volume; Urea	2021
New saviour for an old problem: Omecamtiv mecarbil for systolic heart failure. The journal of the Royal College of Physicians of Edinburgh, 2021, Volume: 51, Issue:1 Topics: Heart Failure; Heart Failure, Systolic; Humans; Urea	2021
Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline. Pharmacology research & perspectives, 2021, Volume: 9, Issue:3 Topics: Adrenergic alpha-Agonists; Adult; Aged; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Contraction; Norepinephrine; Urea; Ventricular Function	2021
Comprehensive in vitro pro-arrhythmic assays demonstrate that omecamtiv mecarbil has low pro-arrhythmic risk. Clinical and translational science, 2021, Volume: 14, Issue:4 Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Computer Simulation; Dogs; Drug Evaluation, Preclinical; Heart Failure; Heart Ventricles; Humans; Isolated Heart Preparation; Myocytes, Cardiac; Primary Cell Culture; Purkinje Fibers; Rabbits; Urea	2021
Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling. Journal of molecular and cellular cardiology, 2021, Volume: 158 Topics: Actomyosin; Animals; Animals, Newborn; Benzamides; Benzylamines; Cardiac Myosins; Cell Line; Dioxoles; Heart Failure; Humans; Induced Pluripotent Stem Cells; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Myofibroblasts; Rats; Rats, Sprague-Dawley; Receptor, Transforming Growth Factor-beta Type I; Sarcomeres; Signal Transduction; Swine; Tissue Engineering; Tissue Scaffolds; Uracil; Urea; Ventricular Remodeling	2021
Omecamtiv Mecarbil in Systolic Heart Failure. The New England journal of medicine, 2021, May-20, Volume: 384, Issue:20 Topics: Cardiac Myosins; Heart Failure, Systolic; Humans; Stroke Volume; Urea	2021
Omecamtiv Mecarbil in Systolic Heart Failure. The New England journal of medicine, 2021, May-20, Volume: 384, Issue:20 Topics: Cardiac Myosins; Heart Failure, Systolic; Humans; Stroke Volume; Urea	2021
Omecamtiv Mecarbil in Systolic Heart Failure. The New England journal of medicine, 2021, May-20, Volume: 384, Issue:20 Topics: Cardiac Myosins; Heart Failure, Systolic; Humans; Stroke Volume; Urea	2021
Omecamtiv Mecarbil in Systolic Heart Failure. Reply. The New England journal of medicine, 2021, 05-20, Volume: 384, Issue:20 Topics: Heart Failure, Systolic; Humans; Stroke Volume; Urea	2021
Omecamtiv Mecarbil: A Personalized Treatment for Patients With Severely Impaired Ejection Fraction. Journal of the American College of Cardiology, 2021, 07-13, Volume: 78, Issue:2 Topics: Humans; Precision Medicine; Stroke Volume; Urea; Ventricular Function, Left	2021
Danicamtiv Enhances Systolic Function and Frank-Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium. Journal of the American Heart Association, 2021, 06-15, Volume: 10, Issue:12 Topics: Animals; Cardiotonic Agents; Cell Line; Humans; Induced Pluripotent Stem Cells; Kinetics; Male; Middle Aged; Models, Cardiovascular; Myocardial Contraction; Myocytes, Cardiac; Sus scrofa; Systole; Tissue Engineering; Tissue Scaffolds; Urea	2021
Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. Clinical drug investigation, 2021, Volume: 41, Issue:7 Topics: Administration, Oral; Adult; Area Under Curve; Diarrhea; Drug Interactions; Female; Half-Life; Healthy Volunteers; Humans; Least-Squares Analysis; Male; Metformin; Middle Aged; Organic Cation Transport Proteins; ROC Curve; Substrate Specificity; Tablets; Urea	2021
Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil. Clinical pharmacology in drug development, 2021, Volume: 10, Issue:12 Topics: Administration, Oral; Area Under Curve; Humans; Tablets; Urea	2021
Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects. Clinical pharmacology in drug development, 2022, Volume: 11, Issue:2 Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Interactions; Healthy Volunteers; Humans; Urea	2022
Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects. Clinical pharmacology in drug development, 2022, Volume: 11, Issue:1 Topics: Drug Interactions; Healthy Volunteers; Humans; Omeprazole; Proton Pump Inhibitors; Urea	2022
The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation. Physiological reports, 2021, Volume: 9, Issue:16 Topics: Animals; Aortic Valve Insufficiency; Cardiotonic Agents; Heart Ventricles; Infusions, Intravenous; Male; Rats; Rats, Wistar; Stroke Volume; Systole; Urea	2021
Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model. Clinical and translational science, 2021, Volume: 14, Issue:6 Topics: Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomedical Research; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Models, Biological; Neoplasm Proteins; Rosuvastatin Calcium; Urea	2021
[CLINICAL EFFICACY OF A REPRESENTATIVE OF A NEW CLASS OF INOTROPIC AGENTS - THE DIRECT ACTIVATOR OF MYOSIN OF CARDIOMYOCYTES OMECAMTIV MECARBIL IN HEART FAILURE WITH A REDUCED EJECTION FRACTION]. Georgian medical news, 2021, Issue:318 Topics: Heart Failure; Humans; Myocytes, Cardiac; Myosins; Quality of Life; Stroke Volume; Treatment Outcome; Urea	2021
Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects. Clinical pharmacology in drug development, 2022, Volume: 11, Issue:3 Topics: Amiodarone; Clinical Trials, Phase I as Topic; Digoxin; Drug Interactions; Healthy Volunteers; Humans; Urea	2022
Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action. Journal of pharmacokinetics and pharmacodynamics, 2022, Volume: 49, Issue:1 Topics: Animals; Myocardial Contraction; Myocytes, Cardiac; Myosins; Rats; Urea	2022
Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction. Journal of cardiovascular pharmacology, 2022, 04-01, Volume: 79, Issue:4 Topics: Healthy Volunteers; Heart Failure; Humans; Stroke Volume; Urea	2022
Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations. American journal of physiology. Heart and circulatory physiology, 2022, 03-01, Volume: 322, Issue:3 Topics: Adenosine Triphosphate; Animals; Calcium; Cardiotonic Agents; Cell Line; Cells, Cultured; Cellular Reprogramming Techniques; Humans; Induced Pluripotent Stem Cells; Mitochondria, Heart; Myocardial Contraction; Myocytes, Cardiac; Rats; Rats, Wistar; Reactive Oxygen Species; Urea	2022
Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model. PloS one, 2022, Volume: 17, Issue:2 Topics: Animals; Cardiopulmonary Resuscitation; Heart Arrest; Male; Myocardial Contraction; Nervous System Diseases; Rats; Rats, Wistar; Stroke Volume; Urea; Ventricular Dysfunction; Ventricular Function, Left	2022
A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin? European heart journal, 2022, 06-14, Volume: 43, Issue:23 Topics: Atrial Fibrillation; Digoxin; Heart Failure; Humans; Urea	2022
Omecamtiv Mecarbil as a Therapy for Heart Failure With Low Ejection Fraction. JAMA, 2022, 07-19, Volume: 328, Issue:3 Topics: Heart Failure; Humans; Stroke Volume; Urea; Ventricular Function, Left	2022
Omecamtiv mecarbil for patients with severe systolic dysfunction and hypotension. European heart journal, 2022, 12-21, Volume: 43, Issue:48 Topics: Blood Pressure; Heart Failure; Humans; Hypotension; Stroke Volume; Urea; Ventricular Dysfunction, Left	2022
Omecamtiv Mecarbil: Decisional Dilemmas and Regulatory Science - Opportunities for Improvement? Journal of cardiac failure, 2023, Volume: 29, Issue:5 Topics: Heart Failure; Humans; Myocardial Contraction; Stroke Volume; Urea	2023
Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure. The American journal of cardiology, 2023, 10-15, Volume: 205 Topics: Heart Failure; Humans; Urea	2023